Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NantKwest (NK) initiated with an Overweight at Piper Sandler....
Biogen's completed Biologics License Application submission for aducanumab "finally begins the big journey of what will be a hotly debated FDA review," Jefferies analyst Michael...
JPMorgan analyst Paul Coster upgraded Nikola to Overweight from Neutral with an unchanged price target of $45. The stock in premarket trading is up 8.5%...
The S&P was little changed near midday, as markets continued to weigh rebounding economic data and continued stimulus measures against the daily reports of COVID-19...
KeyBanc analyst Donald Hooker raised the firm's price target on Livongo Health to $105 from $85 and reiterates an Overweight rating on the shares. The...